Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1973

Topical anti-microbial agents for the prevention of STDs and other viral infections

Inventors: Judy Lieberman, Manjunath Narasimhaswamy

Invention Types: Therapeutics

Research Areas: Infectious Disease

Keywords: siRNA

For More Information Contact:  Dietz, Ryan

 

Invention Description:

The novel agents of this invention comprise short interference RNAs (siRNAs) that either down-regulate genes necessary for viral reproduction or down-regulate the cellular receptors necessary for infection thereby preventing entry of the virus or microbe into target cells such as macrophages and T cells. The preferred method of delivery of the siRNAs into human subjects comprises applying a topical composition consisting of naked or chemically modified double-stranded siRNAs conjugated to a pharmaceutically acceptable carrier. Sequences and vectors are claimed for siRNAs that inhibit the expression of viral genes. Recent studies have shown that siRNA delivery and gene silencing can be achieved in the mouse vagina with lasting results.

Applications:

The present invention provides compositions and methods for prevention of sexually transmitted diseases including but not limited to HIV, hepatitis B, herpes and papilloma virus infection by modulating the expression of the corresponding genes through RNA interference or post-transcriptional gene silencing.

Competitive Advantages:

Delivery mediums may include eye drops, lip balm, lip stick, ointment, cream, paste, emulsion, foam, jelly, gels or a spray.

Business Opportunity:

Exclusive License

Key Publications:
•Wheeler LA, Trifonova R, Vrbanac V, et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest. 2011 Jun;121(6):2401-12.

•Wu Y, Navarro F, Lal A, et al. Durable protection from herpes simplex virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host & Microbe. 2009 Jan 22;5(1):84-94

•Palliser D, Chowdhury D, Wang QY, et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 2006 Jan 5;439(7072):89-94.

•Novina CD, Murray MF, Dykxhoorn DM, et al. siRNA-directed inhibition of HIV-1 infection. Nat Med. 2002 Jul;8(7):681-6.

Related Publications:
US Patent Issued #7,696,179

IPStatus: Patented